US4367233A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibitors of mammalian collagenase
Assignee: Wyeth LLC
•
Filing: 1981-10-02
•
Granted: 1983-01-04
•
Expires: 2001-10-02
Abstract
Abstract A method of inhibiting mammalian collagenase by using α-phenyl-2-(aza)benzothiazolylthioglycolic acids and derivatives thereof, and the pharmaceutically acceptable salts thereof.
Inventors
- 👤 Donald E. Clark
- 👤 Norman H. Grant
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 17:29
CPC Classifications
C; C07; C07D; C07D513/00; C07D513/02; C07D513/04; C07D277/00; C07D277/60; C07D277/62; C07D277/68; C07D277/70; C07D277/74
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
106 words
A method of inhibiting collagenase in mammals afflicted with a disease state in which collagen is broken down by collagenase, which comprises administering to such an afflicted mammal an amount sufficient to reverse said collagenase-induced collagen break down of a collagenase inhibitor having the formula: ##STR4## wherein R 1 is hydrogen, halo, nitro, amino, lower alkyl, lower alkoxy, trifluoromethyl or hydroxy; R 2 is fluorine, chlorine, bromine, lower alkyl, lower alkoxy, amino, nitro or trifluoromethyl; R 3 is hydroxy, lower alkoxy, amino, hydroxy(lower)alkylamino, N-(lower)alkanoylamino(lower)alkoxy or N-arylcarbamoyl(lower)alkylthio; and where the dotted lines represent optional double bonds in the 5,6- and 7,8-positions, and the pharmacologically acceptable salts thereof.
Claim 2
Independent Claim
106 words
A method of inhibiting collagenase in mammals afflicted with a disease state in which collagen is broken down by collagenase, which comprises administering to such an afflicted mammal an amount sufficient to reverse said collagenase-induced collagen break down of a collagenase inhibitor having the formula: ##STR4## wherein R 1 is hydrogen, halo, nitro, amino, lower alkyl, lower alkoxy, trifluoromethyl or hydroxy; R 2 is fluorine, chlorine, bromine, lower alkyl, lower alkoxy, amino, nitro or trifluoromethyl; R 3 is hydroxy, lower alkoxy, amino, hydroxy(lower)alkylamino, N-(lower)alkanoylamino(lower)alkoxy or N-arylcarbamoyl(lower)alkylthio; and where the dotted lines represent optional double bonds in the 5,6- and 7,8-positions, and the pharmacologically acceptable salts thereof.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein the inhibitor is α-(2-benzothiazolylthio)benzeneacetic acid.
Claim 4
Dependent Claim
11 words
The method of claim 1, wherein the inhibitor is α-(5-chlorobenzothiazol-2-ylthio)benzeneacetic acid.
Claim 5
Dependent Claim
15 words
The method of claim 1, wherein the inhibitor is the sodium salt of α-(5-chlorobenzothiazol-2-ylthio)benzeneacetic acid.
Claim 6
Dependent Claim
11 words
The method of claim 1, wherein the inhibitor is α-(5-chlorobenzothiazol-2-ylthio)-α-(p-chlorophenyl)acetic acid.
Claim 7
Dependent Claim
11 words
The method of claim 1, wherein the inhibitor is α-(p-chlorophenyl)-α-(benzothiazol-2-ylthio)acetic acid.
Claim 8
Dependent Claim
14 words
The method of claim 1, wherein the inhibitor is α-(5-chloro-2-benzothiazolylthio)benzene acetic acid, ethyl ester.
Claim 9
Dependent Claim
10 words
The method of claim 1, wherein the inhibitor is α-(5-chlorobenzothiazol-2-ylthio)-α-phenylacetamide.
Claim 10
Dependent Claim
10 words
The method of claim 1, wherein the inhibitor is α-[(5-chloro-2-benzothiazolyl)thio]-N-(2-hydroxyethyl)benzeneacetamide.
Claim 11
Dependent Claim
12 words
The method of claim 1, wherein the inhibitor is α-[(5-chloro-2-benzothiazolyl)thio]acetic acid, [2-(acetylamino)ethyl]-ester.
Claim 12
Dependent Claim
12 words
The method of claim 1, wherein the inhibitor is α-[(5-chloro-2-benzothiazolyl)thio]benzeneethanethioc acid S-[2-(2-naphthalenylamino)-2-oxoethyl]ester.
Claim 13
Dependent Claim
11 words
The method of claim 1, wherein the inhibitor is α-phenyl-α-[(4,5,6,7-tetrahydrobenzothiazol-2-yl)thio]acetic acid.
Claim 14
Dependent Claim
11 words
The method of claim 1, wherein the inhibitor is α-[(6-nitro-2-benzothiazolyl)thio]benzeneacetic acid.
References Cited (Backward Citations)
US4294839A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-01-03 | 1986-07-05 | 1987-01-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-01-03 | 1990-07-05 | 1991-01-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-01-03 | 1994-07-05 | 1995-01-04 | $7700.00 | Window Closed / Lapsed |